

# Head and Neck Cancer Pathways

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

**Pathology:** \_\_\_\_\_

**Stage:** \_\_\_\_\_

**Line of Therapy:**  Neoadjuvant/Pre-Op  Adjuvant/Post-Op

**ECOG Performance Status:** \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

1<sup>st</sup> Line

2<sup>nd</sup> Line

## Non-Nasopharyngeal (Squamous Cell Carcinoma) | Candidate for Local Therapy (M0) | Primary Systemic Therapy or Post-Operative Systemic Therapy

High dose cisplatin\* with concurrent RT

## Non-Nasopharyngeal (Squamous Cell Carcinoma) | Metastatic and Recurrent Disease | First Line of Therapy (1<sup>st</sup> line)

Carboplatin, fluorouracil (5FU), and cetuximab (Erbixux)

Cisplatin, fluorouracil (5FU), and cetuximab (Erbixux)

## Non-Nasopharyngeal (Squamous Cell Carcinoma) | Metastatic and Recurrent Disease | Second and Subsequent Lines of Therapy (2<sup>nd</sup> line+)

Nivolumab (Opdivo)

Paclitaxel

## Nasopharynx | Candidate for Local Therapy (M0) | Primary Systemic Therapy

High dose cisplatin\* with concurrent RT

Cisplatin and gemcitabine (Gemzar) followed by concurrent cisplatin/RT

## Nasopharynx | Metastatic and Recurrent Disease | First and Subsequent Lines of Therapy (1<sup>st</sup> Line+)

Carboplatin

Cisplatin

Cisplatin† and gemcitabine (Gemzar)

Cisplatin† and paclitaxel

Fluorouracil (5FU)

Gemcitabine (Gemzar)

Methotrexate

Paclitaxel

\*High dose cisplatin refers to dosing to achieve total dose of 200-300 mg/m<sup>2</sup> of cisplatin over the course of the radiotherapy. There are several different appropriate cisplatin schedules that may be used.

†Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

**Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.**



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Last review: 8/27/2019 | Effective date: 11/18/2019

Appropriate.Safe.Affordable

© 2019 AIM Specialty Health  
9011-1119